-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
The combination of immune and anti-angiogenic drugs "combination fist" breaks the traditional treatment pattern
The annual global oncology event, the European Society for Medical Oncology (ESMO), was held
The preliminary results of the SUNRISE study are remarkable,
Long-lasting, safe and tolerable
Encouraged by the results of the Phase I research results, in order to further explore the efficacy and safety of Xindilizumab combined with anlotinib in the first-line treatment of metastatic NSCLC and achieve the purpose of "dechemotherapy" in clinical treatment, Professor Han Baohui's team carried out a SUNRISE study on Xindilizumab plus anlotinib versus standard therapy[1].Shanghai Chest Hospital
Professor, Doctoral Supervisor, Honorary Director of Respiratory Medicine
Shanghai leading talent, outstanding discipline leader
Executive Dean of Chinese Lung Cancer Academy
Former Chairman of the CSCO Tumor Vascular Targeting Committee
Vice Chairman of the Precision Diagnosis and Treatment Committee of Cancer of the Chinese Anti-Cancer Association
Chairman of the Oncology Branch of the Asia-Pacific Medical Bioimmunology Society
Vice Chairman of Shanghai Anti-Cancer Association (8th)
Vice Chairman of the Special Committee of Tumor Target Molecules of Shanghai Medical Association, and later Chairman of the Committee
Vice President of the Respiratory Society of Shanghai Medical Doctor Society
He is good at lung cancer diagnosis and multidisciplinary treatment, biological immune targeted therapy for lung cancer and clinical research on
[1] Baohui Han,Tianqing Chu,Zhuang Yu,et al.
[2] Wang Jingyi,Peng Wenying,Jiang Meilin,Wu Lin.
[3] Remon J,Passiglia F,Ahn MJ,et al.
Peng Minhua,Chen Gongyan.
[5] Manegold C,Dingemans A M C,Gray J E,et al.
[6] Chu T,Zhong R,Zhong H,et al.
Zhao Sha,Jiang Tao,Zhou Caicun.
[8] NCCN Clinical Practice Guidelines in Oncology:Non-Small Cell Lung Cancer(Version 4.
[9] T.
Csoszi,J.
C.
Yang,A.
Luft,et al.
Pembrolizumab(Pembro)With or Without Lenvatinib(Lenva)in First-Line Metastatic NSCLC With PD-L1 TPS≥1%(LEAP-007):A Phase 3,Randomized,Double-Blind Study.
2021 ESMO Abstract 120O.
